{"title":"实施电子健康记录警报以改善成人癌症患者阿片类药物过量风险的纳洛酮共同处方。","authors":"Kristin Begger, Jeanne Burnkrant","doi":"10.6004/jadpro.2025.16.7.24","DOIUrl":null,"url":null,"abstract":"<p><p>The Centers for Disease Control and Prevention and U.S. Public Health Service recommend that clinicians prioritize coprescribing take-home naloxone (THN) for patients with cancer receiving opioids in high doses or in the presence of a concomitant high-risk medication. Despite this, THN coprescribing rates remain low. The aim of this quality improvement project (QIP) was to determine if the implementation of an electronic health record (EHR) alert could result in increased THN coprescribing rates in patients with cancer at risk for opioid overdose. This pre- and post-intervention QIP was conducted in an outpatient medical oncology clinic in the Mountain West region of the US. Opioid prescriptions for the management of cancer-related pain totaling ≥ 100 morphine milligram equivalents (MME) per day or with a concomitant high-risk medication were eligible for inclusion (<i>N</i> = 224). An EHR alert was developed to notify the provider when eligibility criteria were met, prompting them to coprescribe THN. The primary outcome measure to increase THN coprescribing rates for opioid prescriptions totaling ≥ 100 MME per day was 38% at the end of the post-intervention period, a 29 percentage point increase from baseline (odds ratio [OR] = 6.57, 95% confidence interval [CI] = 1.85-23.39, <i>p</i> = .003). The coprescribing rate for opioid prescriptions with a high-risk medication was 57% at completion of the project, a 53 percentage point increase from baseline (OR = 30.67, 95% CI = 8.91-105.59, <i>p</i> < .001). This project established the practicality and success of THN coprescribing alert implementation and can be utilized as a roadmap for other practices to achieve safe opioid prescribing for patients with cancer.</p>","PeriodicalId":94110,"journal":{"name":"Journal of the advanced practitioner in oncology","volume":" ","pages":"1-9"},"PeriodicalIF":0.0000,"publicationDate":"2025-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12492504/pdf/","citationCount":"0","resultStr":"{\"title\":\"Implementation of an Electronic Health Record Alert to Improve Naloxone Coprescribing for Adult Patients With Cancer at Risk for Opioid Overdose.\",\"authors\":\"Kristin Begger, Jeanne Burnkrant\",\"doi\":\"10.6004/jadpro.2025.16.7.24\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>The Centers for Disease Control and Prevention and U.S. Public Health Service recommend that clinicians prioritize coprescribing take-home naloxone (THN) for patients with cancer receiving opioids in high doses or in the presence of a concomitant high-risk medication. Despite this, THN coprescribing rates remain low. The aim of this quality improvement project (QIP) was to determine if the implementation of an electronic health record (EHR) alert could result in increased THN coprescribing rates in patients with cancer at risk for opioid overdose. This pre- and post-intervention QIP was conducted in an outpatient medical oncology clinic in the Mountain West region of the US. Opioid prescriptions for the management of cancer-related pain totaling ≥ 100 morphine milligram equivalents (MME) per day or with a concomitant high-risk medication were eligible for inclusion (<i>N</i> = 224). An EHR alert was developed to notify the provider when eligibility criteria were met, prompting them to coprescribe THN. The primary outcome measure to increase THN coprescribing rates for opioid prescriptions totaling ≥ 100 MME per day was 38% at the end of the post-intervention period, a 29 percentage point increase from baseline (odds ratio [OR] = 6.57, 95% confidence interval [CI] = 1.85-23.39, <i>p</i> = .003). The coprescribing rate for opioid prescriptions with a high-risk medication was 57% at completion of the project, a 53 percentage point increase from baseline (OR = 30.67, 95% CI = 8.91-105.59, <i>p</i> < .001). This project established the practicality and success of THN coprescribing alert implementation and can be utilized as a roadmap for other practices to achieve safe opioid prescribing for patients with cancer.</p>\",\"PeriodicalId\":94110,\"journal\":{\"name\":\"Journal of the advanced practitioner in oncology\",\"volume\":\" \",\"pages\":\"1-9\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-09-02\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12492504/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of the advanced practitioner in oncology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.6004/jadpro.2025.16.7.24\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of the advanced practitioner in oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.6004/jadpro.2025.16.7.24","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
美国疾病控制与预防中心和美国公共卫生服务中心建议临床医生优先为接受高剂量阿片类药物治疗或同时服用高风险药物的癌症患者开带回家纳洛酮(THN)。尽管如此,THN的处方率仍然很低。本质量改进项目(QIP)的目的是确定电子健康记录(EHR)警报的实施是否会导致有阿片类药物过量风险的癌症患者THN共处方率增加。这项干预前和干预后的QIP在美国西部山区的一家门诊肿瘤医学诊所进行。用于治疗癌症相关疼痛的阿片类药物处方每天总剂量≥100吗啡毫克当量(MME)或同时使用高风险药物符合纳入条件(N = 224)。当符合资格标准时,开发了EHR警报通知提供者,提示他们共同开THN。干预期结束时,阿片类药物处方合计每天≥100 MME的THN共处方率增加的主要结局指标为38%,较基线增加29个百分点(优势比[OR] = 6.57, 95%可信区间[CI] = 1.85-23.39, p = 0.003)。在项目完成时,阿片类药物处方与高危药物的共处方率为57%,比基线增加53个百分点(OR = 30.67, 95% CI = 8.91-105.59, p < .001)。本项目确立了THN共同处方警报实施的可行性和成功性,并可作为其他实践实现癌症患者阿片类药物安全处方的路线图。
Implementation of an Electronic Health Record Alert to Improve Naloxone Coprescribing for Adult Patients With Cancer at Risk for Opioid Overdose.
The Centers for Disease Control and Prevention and U.S. Public Health Service recommend that clinicians prioritize coprescribing take-home naloxone (THN) for patients with cancer receiving opioids in high doses or in the presence of a concomitant high-risk medication. Despite this, THN coprescribing rates remain low. The aim of this quality improvement project (QIP) was to determine if the implementation of an electronic health record (EHR) alert could result in increased THN coprescribing rates in patients with cancer at risk for opioid overdose. This pre- and post-intervention QIP was conducted in an outpatient medical oncology clinic in the Mountain West region of the US. Opioid prescriptions for the management of cancer-related pain totaling ≥ 100 morphine milligram equivalents (MME) per day or with a concomitant high-risk medication were eligible for inclusion (N = 224). An EHR alert was developed to notify the provider when eligibility criteria were met, prompting them to coprescribe THN. The primary outcome measure to increase THN coprescribing rates for opioid prescriptions totaling ≥ 100 MME per day was 38% at the end of the post-intervention period, a 29 percentage point increase from baseline (odds ratio [OR] = 6.57, 95% confidence interval [CI] = 1.85-23.39, p = .003). The coprescribing rate for opioid prescriptions with a high-risk medication was 57% at completion of the project, a 53 percentage point increase from baseline (OR = 30.67, 95% CI = 8.91-105.59, p < .001). This project established the practicality and success of THN coprescribing alert implementation and can be utilized as a roadmap for other practices to achieve safe opioid prescribing for patients with cancer.